ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
August 27 2018 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the following presentations by Company
management at upcoming investor conferences will be webcast:
- 20th Annual Rodman
& Renshaw Global Investment Conference, sponsored by H.C.
Wainwright & Co., LLCSeptember 5 at 12:30pm ET
- Morgan Stanley 16th
Annual Global Healthcare ConferenceSeptember 13 at 3:30pm
ET
A webcast of each presentation will be accessible live through
the “Investors” section of the Company’s website,
www.immunogen.com; a replay will be available in the same location
for approximately two weeks.
ABOUT IMMUNOGENImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.” Our
lead product candidate, mirvetuximab soravtansine, is in a Phase 3
study for folate receptor alpha (FRα)-positive platinum-resistant
ovarian cancer, and in Phase 1b/2 testing in combination regimens.
Our novel IGN candidates for hematologic malignancies, IMGN779 and
IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180827005536/en/
INVESTOR RELATIONS CONTACTImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMEDIA
CONTACTImmunoGen, Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI ConsultingRobert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024